Treatment of Pneumocystis jirovecii Pneumonia

First-Line Alternative Options

• The American College of Oncology recommends clindamycin plus primaquine as the preferred alternative to trimethoprim-sulfamethoxazole for PJP treatment, showing superior efficacy compared to pentamidine 1
• For patients with mild-to-moderate PJP, atovaquone or clindamycin plus primaquine are preferred alternatives, according to the Annals of Oncology 1
• Clindamycin plus primaquine is preferred over pentamidine for severe PJP, as stated by the Annals of Oncology 1

Considerations for Selecting Alternative Therapy

• The Annals of Oncology suggests checking G6PD levels before initiating primaquine or dapsone due to the risk of hemolytic reactions in G6PD-deficient patients 2
• The Blood Cancer Journal recommends assessing renal function when selecting alternatives, as pentamidine has significant renal toxicity 1

Medication-Specific Guidelines

• Clindamycin plus primaquine is recommended as the most effective second-line therapy for patients who fail or develop toxicity to trimethoprim-sulfamethoxazole, according to the Annals of Oncology 1

Adjunctive Therapy

• The Annals of Oncology suggests considering adjunctive glucocorticosteroids in patients with severe PJP and critical respiratory insufficiency 1

Prevention After Treatment

• The Annals of Oncology recommends secondary prophylaxis to prevent recurrence after successful PJP treatment, with options including trimethoprim-sulfamethoxazole, monthly aerosolized pentamidine, dapsone, or atovaquone 1, 2
• The Blood Cancer Journal suggests using dapsone (with G6PD testing) or atovaquone as options for secondary prophylaxis 2